Auron Therapeutics Welcomes Glenn Goddard as CFO to Drive Strategic Growth

Auron Therapeutics, a biotechnology company focused on targeting cell-state plasticity to transform cancer and inflammatory disease treatment, has appointed Glenn Goddard as its new Chief Financial Officer. With over 25 years of experience in biotech finance and strategic growth, Goddard brings a wealth of expertise in fundraising, investor relations, and corporate development. His leadership will be crucial as Auron advances its lead program, AUTX-703, into clinical trials and expands its pipeline of first-in-class therapies.

Kate Yen, Ph.D., Founder and CEO of Auron, expressed confidence in Goddard’s ability to guide the company’s financial strategy, stating, “His experience in biotech financing and strategic growth will be instrumental as we take the next steps in our mission.” Goddard, who previously led financial operations at Intellia Therapeutics and Agios Pharmaceuticals, has helped raise over $3 billion throughout his career. Now, at Auron, he aims to strengthen the company’s financial position and support its vision of delivering life-changing treatments to patients with limited options.